Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS): 9 pipeline candidates · 1 upcoming catalyst · ~66 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
65.9 months
D/E 0.05 · 7% dilution
Lead: Approved
9 candidates
1 upcoming, next in ~897d
2 buys · 0 sells (180d)
A transparent, data-derived signal for Corvus Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.0B
Cash
$40.1M
Quarterly Burn
$10.4M
Runway
65.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| ciforadenant | Phase 1 |
| CPI-182 | Preclinical |
| CPI-935 | Preclinical |
| hu6 | Phase 2 |
| mupadolimab | Preclinical |
| next-generation ITK inhibitor preclinical candidates | Preclinical |
| soquelitinib | Phase 3 |
| soquelitinib (CPI-818) | Phase 3 |
| treatments | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$1.04B
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 7,165,006 | $104.8M |
| vanguard capital management llc | 6,469,076 | $94.6M |
| blackrock, inc. | 6,160,422 | $90.1M |
| perceptive advisors llc | 4,584,882 | $67.1M |
| state street corp | 3,565,992 | $52.2M |
| adams street partners llc | 3,275,616 | $47.9M |
| morgan stanley | 2,498,825 | $36.6M |
| deep track capital, lp | 2,491,539 | $36.5M |
| wellington management group llp | 2,318,517 | $33.9M |
| commodore capital lp | 2,258,735 | $33.0M |
Showing top 10 of 164 institutional holders of Corvus Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Corvus Pharmaceuticals, Inc.'s pipeline?
Corvus Pharmaceuticals, Inc. (CRVS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Corvus Pharmaceuticals, Inc.'s lead drug candidate?
Corvus Pharmaceuticals, Inc.'s most advanced tracked candidate is ciforadenant (Phase 1) for metastatic RCC.
What is Corvus Pharmaceuticals, Inc.'s next catalyst?
Corvus Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soqu" — expected December 1, 2028.
What is Corvus Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Corvus Pharmaceuticals, Inc. has approximately 65.9 months of cash runway.
What is Corvus Pharmaceuticals, Inc.'s market capitalization?
Corvus Pharmaceuticals, Inc.'s market capitalization is approximately $1.0B.
Get the full picture on Corvus Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.